A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006-2013).
Multi-drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naïve feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown. This study evaluated the efficacy and tolerability of lomustine for the treatment of feline GI lymphoma. Thirty-two cats with histologically or cytologically confirmed intermediate/large cell GI lymphoma were evaluated retrospectively. Factors assessed included clinical signs, hematologic/biochemical parameters and use of l-asparaginase at induction. A response rate of 50% (16/32), with median duration of response of 302 days (range 64-1450 days), was found. Median progression-free interval was 132 days (range 31-1450 days), with overall median survival time of 108 days (range 4-1488 days). History of hyporexia, presence of anaemia and dose of lomustine were significantly associated with progression-free survival. Overall, lomustine is a well-tolerated and effective treatment for feline GI lymphoma.
Department of Clinical Sciences, Cummings Veterinary Medical Center, Tufts University, North Grafton, MA, USA.
S E
SE
Rau
Department of Clinical Sciences, Cummings Veterinary Medical Center, Tufts University, North Grafton, MA, USA.
K E
KE
Burgess
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D008130:Lomustine / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D008130:Lomustine
feline; gastrointestinal; lomustine; lymphoma